This article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
Once-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Other kidney cancer research included an 8-gene panel that was able to predict high tumor grade in biopsy specimens and a review of perioperative transfusion’s effect on recurrence-free and overall survival.
To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.
In a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.